Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma

1. Rodriguez-Otero, P.
2. Ayers, D.
3. Cope, S.
4. Davies, F.E.
5. Delforge, M.
6. Mojebi, A.
7. Jansen, J.P.
8. Weisel, K.
9. Hege, K.
10. Dhanasiri, S.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1080/10428194.2021.1913143 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus